Yael Eshet

Yael Eshet

Auto-generated profile, based on publicly available information

Yael Eshet

Affiliation Department of Nuclear Imaging, Sheba Medical Center, Ramat Gan, Israel

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2021 in Science
Verified
Journal Article
Closed access
PDF file
EBErez N. Baruch
Erez N. Baruch
IYIlan Youngster
Ilan Youngster
GBGuy Ben-Betzalel
Guy Ben-Betzalel
RORona Ortenberg
Rona Ortenberg
ALAdi Lahat
Adi Lahat
BBBen Boursi
Ben Boursi
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573

1 September 2021 in Radiology
Verified
Journal Article
Closed access
YEYael Eshet
Yael Eshet
NTNoam Tau
Noam Tau
YAYousef Alhoubani
Yousef Alhoubani
NKNayroz Kanana
Nayroz Kanana
LDLiran Domachevsky
Liran Domachevsky
MEMichal Eifer
Michal Eifer
Ipsilateral avid axillary lymph node uptake at FDG PET/CT persists in 29% (49 of 169) of patients between 7 to 10 weeks after the second dose of the mRNA-based BNT162b2 COVID-19 vaccination.

14 January 2023 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
YEYael Md Eshet
Yael Md Eshet
NTNoam Tau
Noam Tau
SASara Apter
Sara Apter
NNNoam Nissan
Noam Nissan
KLKeren Levanon
Keren Levanon
LDLiran Domachevsky
Liran Domachevsky
Purpose: Invasive lobular breast cancer (ILC) may be hard to detect using conventional imaging modalities and usually shows less avidity to 18F-FDG PET/CT. 68Ga–fibroblast activation protein inhibitor (FAPI) PET/CT has shown promising results in detecting non–18F-FDG–avid cancers. We aimed to assess the feasibility of detecting metastatic disease in patients with non–18F-FDG–avid ILC. Methods: This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18F-FDG avid. The patients underwent 68Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time. Results: Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone (P = 0.022), especially in infiltrative soft tissue and serosal locations. Conclusions: This small pilot trial suggests a role for 68Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.

1 December 2011 in Autoimmunity Reviews
Verified
Journal Article
Closed access
YEYael Eshet
Yael Eshet
RPRachel Pauzner
Rachel Pauzner
OGOrly Goitein
Orly Goitein
PLPnina Langevitz
Pnina Langevitz
IEIris Eshed
Iris Eshed
EKEli Konen
Eli Konen

17 June 2023 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
YEYael Md Eshet
Yael Md Eshet
NTNoam Tau
Noam Tau
KLKeren Levanon
Keren Levanon
RBRinat Bernstein-Molho
Rinat Bernstein-Molho
OGOfer Globus
Ofer Globus
LDLiran Domachevsky
Liran Domachevsky
Purpose: 68Ga–fibroblast activation protein inhibitor (FAPI), a new PET/CT radiotracer targeting cancer-associated fibroblasts in tumor microenvironment, can detect many types of cancer. We aimed to assess whether it can also be used for response assessment and follow-up. Methods: We followed up patients with FAPI-avid invasive lobular breast cancer (ILC) before and after treatment changes and correlated qualitative maximal intensity projection images and quantitative tumor volume with CT results and blood tumor biomarkers. Results: Six consenting ILC breast cancer patients (53 ± 8 years old) underwent a total of 24 scans (baseline for each patient and 2–4 follow-up scans). We found a strong correlation between 68Ga-FAPI tumor volume and blood biomarkers (r = 0.7, P < 0.01), but weak correlation between CT and 68Ga-FAPI maximal intensity projection–based qualitative response assessment. Conclusions: We found a strong correlation between ILC progression and regression (as assessed by blood biomarkers) and 68Ga-FAPI tumor volume. 68Ga-FAPI PET/CT could possibly be used for disease response assessment and follow-up.

1 July 2022 in Radiology: Imaging Cancer
Verified
Journal Article
Closed access
MKMaximiliano Klug
Maximiliano Klug
SASara Apter
Sara Apter
YEYael Eshet
Yael Eshet
EMEdith Michelle Marom
Edith Michelle Marom